No Data
Sangamo Therapeutics (NASDAQ:SGMO Shareholders Incur Further Losses as Stock Declines 15% This Week, Taking Five-year Losses to 89%
TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
Sangamo Reports Updated Data for Gene Therapy Candidate ST-920
Express News | Sangamo Therapeutics Inc - Isaralgagene Civaparvovec Generally Well-Tolerated With Most Adverse Events Grade 1-2
Express News | Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
